SUBSCRIBE
SUBSCRIBE
News   Business

Medivir AB Announces Bristol-Myers Squibb (Jobs) Has Terminated Their Agreement for the Development of Medivir’s Preclinical Polymerase Inhibitor, MIV-170

July 6, 2007 | 
1 min read

DOW JONES NEWSWIRES -- Medivir AB said Bristol-Myers Squibb Co. (BMY) has terminated the development of the preclinical HIV compound MIV-170 because the compound didn't meet the profile desired by Bristol-Myers.

Alliances
Bristol Myers Squibb Company
MORE ON THIS TOPIC
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
4DMT Thins Early-Stage Workforce, Focuses on Late-Stage Activities
July 3, 2025
 · 
152 min read
 · 
BioSpace Editorial Staff
Podcast
CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP
July 2, 2025
 · 
1 min read
 · 
Heather McKenzie
A contemporary artistic collage depicting a hand holding pills, passing them to another hand. The concept of medication and treatment.
Collaboration
Argenx Makes $1.5B+ Play for UNP’s Macrocyclic Peptides Aimed at ‘Undruggable’ Targets
July 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage, female palms in the orange circle, a bag of money. Concept of business and finance.
Mergers & acquisitions
AbbVie Plunks Down $2.1B for Capstan and Its Novel CAR T Therapies
June 30, 2025
 · 
2 min read
 · 
Dan Samorodnitsky